A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.
Diffuse Large B Cell Lymphoma (DLBCL)
DRUG: Orelabrutinib + R-CHOP|DRUG: Placebo + R-CHOP
Progression free survival (PFS), Progression free survival (PFS) accessed by independent review committee (IRC), Up to 3 years and 9 months|Complete response rate (CRR) by independent review committee (IRC), Complete response rate (CRR) at the completion of combination therapy accessed by independent review committee (IRC), Up to 3 years and 9 months
Complete response rate (CRR) by investigator, Complete response rate (CRR) at the completion of combination therapy accessed by investigator, Up to 3 years and 9 months|Overall response rate (ORR) by independent review committee (IRC) and investigator, Overall response rate (ORR) accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Overall response rate (ORR) at the completion of combination therapy by independent review committee (IRC) and investigator, Overall response rate (ORR) at the completion of combination therapy accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Duration of Response (DOR), Duration of Response (DOR) accessed by independent review committee (IRC) and investigator, Up to 3 years and 9 months|Disease free survival (DFS) rate and event free survival (EFS) rate, 2-year disease free survival (DFS) rate and 2-year event free survival (EFS) rate, Up to 2 years|Overall survival (OS) rate, 2-year overall survival (OS) rate Accessed by independent review committee (IRC) and investigator, Up to 2 years|Occurrence of adverse events and serious adverse events according to CTCAE V5.0., The safety of Orelabrutinib measured by the occurrence of adverse events and serious adverse events according to CTCAE V5.0., Up to 3 years and 9 months
The purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with R-CHOP regimen versus placebo with R-CHOP in the treatment of treatment-naïve patients with MCD subtype DLBCL.